Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

NASDAQ:MRNS

Marinus Pharmaceuticals, Inc.

Last Close

1.42

26/04 20:00

Market Cap

77.18M

Beta: 1.16

Volume Today

17.68K

Avg: 544.92K

PE Ratio

−4.02

PFCF: −4.81

Please Sign In To Use The Chat